Sodium-Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

• Main Authors: Genlong Xue (Author), Xiaolei Yang (Author), Ge Zhan (Author), Xin Wang (Author), Jinghan Gao (Author), Yong Zhao (Author), Xinying Wang (Author), Jiatian Li (Author), Zhenwei Pan (Author), Yunlong Xia (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the main cause of de...